0      0

National Symposium 2014

201 - A Team Approach: The Benefits of Utilizing Longer-Acting Erythropoietin Stimulating Agents (ESAs) in CKD

Apr 15, 2014 7:30am ‐ Apr 15, 2014 9:00am

Standard: $20.00
Members: $0.00


Contact hours available until 4/16/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure:
Speaker(s) have no disclosures to declare.

Planning Committee:
• Annette Hood discloses that she is a member of the Amgen speakers’ bureau.
• Denise Murcek discloses other financial/material support as an employee of the VA Medical Center.
• Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care.
• Kyra Trappett discloses other financial/material support as an employee of DaVita.

Commercial Support and Sponsorship:
Supported by an educational donation from Amgen.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

• Discuss hemoglobin variability and its effect on patient outcomes in ESRD patients.
• Develop a comprehensive knowledge base of the pharmacodynamics of longer acting ESA agents.
• Recognize unit, nursing, and patient factors that may benefit from the implementation of longer acting ESA agents.


  • Christine M. Chmielewski, MS, CRNP, ANP-BC, CNN-NP, Nephrology Nurse Practitioner, Thomas Jefferson University Hospital
  • Jennifer Payton, MHCA, BSN, RN, CNN, Surveyor, National Dialysis Accreditation Commission

You must be logged in and own this session in order to post comments.